Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan

Bibliography

• Adler AI, Stratton IM, Neil HA, Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-19
   PubMed Web of Science ®Google Scholar
• Kannel WB. Role of blood pressure in cardiovascular morbidity and mortality. Prog Cardiovasc Dis 1974;17:5-24
   PubMed Web of Science ®Google Scholar
• Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest 1969;56:43-52
   PubMedGoogle Scholar
• Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. JAMA 1970;214:301-10
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 guidelines for the management of arterial hypertension: the ask force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Black HR, Cannon CP, Treatment of hypertension in the prevention and management of ischemic heart disease. Circulation 2007;115:2761-88
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Invest 2008;28:713-34
   PubMed Web of Science ®Google Scholar
• Wald DS, Law M, Morris JK, Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
   PubMed Web of Science ®Google Scholar
• Waeber B, Feihl F, Ruilope LM. Fixed-dose combinations as initial therapy for hypertension. A review of approved agents and a guide to patient selection. Drugs 2009;69:1761-76
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New Engl J Med 2008;359:2417-28
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
   PubMed Web of Science ®Google Scholar
• Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001;87(8A):37C-43C
   PubMed Web of Science ®Google Scholar
• Saito I, Kushiro T, Ishikawa M, Early antihypertensive efficacy of olmesartan medoxomil. J Clin Hypertens (Greenwich) 2008;10:930-5
   PubMed Web of Science ®Google Scholar
• Barrios V, Boccanelli A, Ewald S, Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig 2007;27:545-58
   PubMed Web of Science ®Google Scholar
• Ewald S, Nickenig G. OLMEBEST-Study: reduction of blood pressure in the treatment of patients with mild-to-moderate essential hypertension - the onset of efficacy. Am J Hypertens 2005;87A: abstract P-225
   Google Scholar
• Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002;16(Suppl 2):S24-8
   PubMedGoogle Scholar
• Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens Suppl 2001;19:S49-56
   PubMedGoogle Scholar
• Basile JN, Chrysant S. The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens 2006;20:169-75
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003;17:425-32
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijisq L, Fagard R, Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004;22:847-57
   PubMed Web of Science ®Google Scholar
• Mallion JM, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens 2007;25:2168-77
   PubMed Web of Science ®Google Scholar
• Oparil S, Williams D, Chrysant SG, Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3:283-91,318
   PubMedGoogle Scholar
• Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005;5:41-50
   PubMedGoogle Scholar
• Giles TD, Oparil S, Silfani TN, Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007;9:187-95
   PubMedGoogle Scholar
• Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Investig 2003;23:419-30
   PubMed Web of Science ®Google Scholar
• Fabia MJ, Abdilla N, Oltra R, Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007;25:1327-36
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension. Expert Opin Pharmacother 2008;9:129-36
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004;17:252-9
   PubMed Web of Science ®Google Scholar
• Rump LC, Ambrosioni E, Burnier M, Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens 2006;20:299-301
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Neutel JM, Punzi HA, Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs 2007;7:361-72
   PubMed Web of Science ®Google Scholar
• Chrysant S, Melino M, Karki S, Onset of antihypertensive effect in patients with mild to severe hypertension treated with a combination of amlodipine besylate and olmesartan medoxomil compared with component monotherapy and placebo. J Clin Hypertens 2008;10(Suppl A):A16
   Google Scholar
• Chrysant SG, Melino M, Karki S, The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I, The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderon A, Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J Hum Hypertens 2007;21:479-85
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Antman EM, Black HR, The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation 2006;114:2871-91
   PubMed Web of Science ®Google Scholar
• Nesbitt SD, Julius S. Prehypertension: a possible target for antihypertensive medication. Curr Hypertens Rep 2000;2:356-61
   PubMedGoogle Scholar
• Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002;89(2A):3A-9A, discussion 10A
   PubMed Web of Science ®Google Scholar
• Oparil S, Yarows SA, Patel S, Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-9
   PubMed Web of Science ®Google Scholar
• Pool JL, Schmieder RE, Azizi M, Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartab. Am J Hypertens 2007;20:11-20
   PubMed Web of Science ®Google Scholar